Provectus Biopharmaceuticals, Inc.

Warrants SEC Reporting - Current
Verified Company Profile 5/02/2017
Contact Info
  • 7327 Oak Ridge Highway
  • Suite A
  • Knoxville, TN 37931

Business Description

Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Mar 31, 2017 10-Q
CIK 0000315545
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: DE, USA
Year of Inc. 2002
Employees 2 a/o Apr 28, 2017
Company Officers/Contacts
Timothy C. Scott, Ph.D. President, Interim CEO
Eric Wachter, Ph.D. CTO
Company Directors
Dominic Rodrigues Chairman, Independent Director
Bruce Horowitz Independent Director
Jan E. Koe
Eric Wachter, Ph.D.
Service Providers
Accounting/Auditing Firm
Marcum LLP
750 Third Ave
11th Floor
New York, NY, 10017
United States
Securities Counsel
Baker, Donelson, Bearman, Caldwell and Berkowitz, PC
165 Madison Ave.
Suite 2000
Memphis, TN, 38103
United States
Investor Relations Firm
Allison & Partners
71 Fifth Avenue
7th Floor
New York, NY, 10003
United States
Company History
  • Formerly=Provectus Pharmaceutical, Inc. until 1-2014
  • Formerly=Zamage Digital Imaging, Inc. until 4-02
  • Note=4-1-02 State of Incorporation Colorado changed to Nevada
  • Note=12-31-04 company is in the development stage
  • Formerly=SPM Group, Inc. until 11-01
PVCTW Security Details Other Company Securities
Share Structure
Market Value1 $569,647 a/o Jun 23, 2017
Authorized Shares 28,482,344 a/o Jun 30, 2016
Outstanding Shares 28,482,344 a/o Jun 30, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value Not Available
Transfer Agent(s)
Shareholders of Record Not Available
Short Selling Data
Short Interest 2,780 (0%)
May 15, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security